NeoGenomics, Inc. (NASDAQ: NEO) announced that its RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services (CMS) Molecular Diagnostic Services Program (MolDX). The update includes immunotherapy monitoring for patients with late-stage solid tumors.

The expanded Medicare coverage specifically permits monitoring of response to immune-checkpoint inhibitor therapy in patients with late-stage solid tumors. This development extends the utility of RaDaR ST across the cancer care continuum.

Coverage Expansion Details

This approval marks the third Medicare-covered indication for the RaDaR ST assay. The existing covered indications include:

• HPV-negative head and neck squamous cell carcinoma
• A subset of hormone receptor-positive (HR+), HER2-negative breast cancer

NeoGenomics currently has two additional RaDaR ST submissions pending with MolDX.

Clinical Context and Utility

Immunotherapy is now standard treatment across numerous common solid tumors, including lung cancer, melanoma, bladder cancer, and renal cell carcinoma. Imaging alone often cannot reliably distinguish true response from early treatment-related inflammatory changes, complicating decisions about whether to continue, adjust, or stop therapy.

Longitudinal molecular testing may help identify early signs of progression that might otherwise be missed and clarify response in the context of pseudoprogression. In lung cancer and melanoma alone, immunotherapy accounts for an estimated 55% and 70% of treated cases, respectively.

Evidence for RaDaR ST in the immunotherapy setting has been demonstrated across multiple studies, including melanoma, head and neck, breast, and bladder cancers. In advanced head and neck cancer treated with immune checkpoint blockade, ctDNA dynamics tracked with survival and response to treatment.

Technology Overview

RaDaR ST employs a tumor-informed approach, analyzing up to 48 patient-specific variants identified through whole-exome sequencing to detect ctDNA at a very low variant allele fraction (VAF). It supports three core clinical uses:

• Recurrence-risk assessment after curative-intent surgery
• Recurrence monitoring during surveillance
• Longitudinal treatment-response monitoring during systemic therapy

Across these settings, RaDaR ST has demonstrated strong analytical and clinical performance in numerous published studies spanning multiple solid tumor types with detection as low as 1ppm.

What the Numbers Show

The expansion to a third distinct indication demonstrates broadening regulatory acceptance of the RaDaR ST platform within the Medicare framework. With two further submissions pending, the company is actively pursuing additional coverage expansions beyond the current three approved use cases. CEO Tony Zook described the coverage determination as a cornerstone of the RaDaR ST launch, noting that personalized MRD testing delivers longitudinal molecular insights that complement traditional assessment methods.

NeoGenomics reported second-quarter adjusted earnings per share (EPS) of $0.05, beating the analyst consensus estimate of $0.03 by 66.67 percent. This represents a 66.67 percent increase over earnings of $0.03 per share from the same period last year. The company also reported quarterly sales of $202.000 million, beating the analyst consensus estimate of $196.997 million by 2.54 percent. This is an 11.40 percent increase over sales of $181.330 million in the same period last year.

The filing indicates strong performance across both profitability and top-line metrics relative to market expectations. NeoGenomics surpassed analyst forecasts on both EPS and revenue, signaling robust operational execution during the quarter. The significant beat in EPS suggests effective cost management or higher-than-expected margins, while the revenue beat points to stronger demand or pricing power than anticipated by analysts.

Financial Performance

The company’s financial results for the quarter highlight a notable divergence between earnings growth and revenue growth. While sales grew by 11.40 percent year-over-year, adjusted EPS surged by 66.67 percent over the same comparison period. This disparity indicates that the improvement in profitability was driven by factors beyond mere revenue expansion, such as margin expansion or reduced expenses.

What the Numbers Show

The primary driver of the quarter’s positive sentiment is the substantial outperformance in adjusted EPS. Beating the estimate by 66.67 percent is a material deviation that often triggers upward revisions in analyst models. Furthermore, the fact that both EPS and sales beat their respective estimates suggests broad-based strength rather than a one-off accounting gain. The 11.40 percent year-over-year sales growth provides a solid foundation for this earnings beat, indicating that the company is successfully scaling its operations while maintaining or improving its profit margins.